Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab

Translated title of the contribution: AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab'. Together they form a unique fingerprint.

Medicine & Life Sciences